A Phase 1 interventional study of Ketamine in Suicide, Suicidal Ideation and Depression, sponsored by Lindsay Maguire, MD. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Lindsay Maguire, MD · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing ketamine in Suicidal Ideation — 8 open to participants now, 9 under way, 3 of them phase 3. Ketamine · Suicidal Ideation.
Among the 36 studies testing ketamine in Suicidal Ideation, this one is the 12th largest by planned enrollment, is one of 3 that started in 2024, is one of 5 in phase 1, and was the 30th registered.
570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.
Browse Suicidal Ideation studies →8 of the 36 studies testing ketamine in Suicidal Ideation are open now, in 2 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–70
Joshua Rosenblat · Sites in Canada
Ages 18–70
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Children's Hospital of Eastern Ontario · Sites in Canada
Ages 12–17
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–70
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 135 Suicidal Ideation studies recruiting now, 52 (39%) set no upper age limit and 79 (59%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 12 · Phase 3 7 · Phase 4 8
First in 2012; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 470 interventional studies indexed under Suicidal Ideation.
Median enrollment 22 across the 36 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 36 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Lindsay Maguire, MD as lead sponsor.
Lindsay Maguire, MD has 1 study filed under Suicidal Ideation — fewer than ten, so there is no comparison to draw.
4 of the studies testing ketamine in Suicidal Ideation that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05696691Phase 3The University of Texas Health Science Center at San AntonioKetamine & Crisis Response Plan for Suicidal Ideation in the ED | 2026-12-31 |
| NCT06891300Phase 3The Royal's Institute of Mental Health ResearchUnderstanding and Treating Suicidal Ideation With Ketamine | 2027-03 |
| NCT07810023Endeavor HealthIntramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress | 2027-03 |
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing ketamine in Suicidal Ideation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
In this phase one trial, the investigators' objective is to establish the safety and feasibility of the study dose and route of administration, as well as to provide preliminary data on efficacy in reduction of depressive and suicidal symptoms as well as length of stay. Select patients will be given 0.2mg/kg of ketamine IV and observed in the ED for two hours. Vital signs and symptoms will be monitored. Patients will then be transferred to an admitting psychiatric hospital for definitive care as per standard of care. Surveys will be administered at times 0, 2 hours, 24 hours, and 72 hours to assess depressive and suicidal symptoms. ED providers and nursing staff will be asked to complete a short survey assessing ease of use and feasibility for ED administration for this purpose.
Specific aims are as follows:
570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.
This study's planned enrollment of 50 is below the median of 80 across 470 interventional studies indexed under Suicidal Ideation.
Browse Suicidal Ideation studies →This is the only study on the registry with Lindsay Maguire, MD as lead sponsor.
Compared within Suicidal Ideation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Suicide. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients will receive the experimental drug.
Drug: Ketamine
Patients will receive 0.2mg/kg of IV ketamine
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Safety of use of ketamine for SI in the ED, as assessed by number and severity of reported serious adverse outcomes.
Time frame: 2 hours
Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility]
A questionnaire will be given to providers and nursing staff to assess \[1\] perceived safety, \[2\] provider comfort, \[3\] perceived efficacy, and \[4\] perceived feasibility for ED use as rated on a Likert scale from 1-5, with 5 relaying best perceived outcomes.
Time frame: 2 hours
Change in Suicidal Ideation
Change of SI in ED patients after ketamine administration, as measured by the Columbia Suicide Severity Rating Scale (ideation subscore range 1-5, with higher number indicating increasing suicidal ideation; intensity subscore rating 2-25, with higher number indicating greater severity of suicidal ideation) and Montgomery-Asberg Depression Rating Scale.
Time frame: 72 hours
Hospital Length of Stay
Impact of administration of ketamine on overall psychiatric hospital length of stay.
Time frame: up to 2 weeks
Started May 2024 (actual). Primary completion is estimated for Apr 2026, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine